Filing Details
- Accession Number:
- 0001610717-24-000239
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-05-16 17:51:24
- Reporting Period:
- 2024-05-14
- Accepted Time:
- 2024-05-16 17:51:24
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1676725 | Ideaya Biosciences Inc. | IDYA | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1649119 | S Yujiro Hata | C/O Ideaya Biosciences, Inc. 7000 Shoreline Court, Suite 350 South San Francisco CA 94080 | President And Ceo | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-05-14 | 56,711 | $4.31 | 734,598 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-05-14 | 54,408 | $41.60 | 680,190 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-05-14 | 2,303 | $41.84 | 677,887 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2024-05-15 | 83,856 | $4.31 | 761,743 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-05-15 | 53,592 | $42.57 | 708,151 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-05-15 | 29,761 | $43.48 | 678,390 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-05-15 | 503 | $44.12 | 677,887 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2024-05-16 | 34,433 | $4.31 | 712,320 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-05-16 | 30,084 | $41.73 | 682,236 | No | 4 | S | Direct | |
Common Stock | Disposition | 2024-05-16 | 4,349 | $42.37 | 677,887 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2024-05-14 | 56,711 | $0.00 | 56,711 | $4.31 |
Common Stock | Stock Option (right to buy) | Disposition | 2024-05-15 | 83,856 | $0.00 | 83,856 | $4.31 |
Common Stock | Stock Option (right to buy) | Disposition | 2024-05-16 | 34,433 | $0.00 | 34,433 | $4.31 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
167,743 | 2028-02-26 | No | 4 | M | Direct | |
83,887 | 2028-02-26 | No | 4 | M | Direct | |
49,454 | 2028-02-26 | No | 4 | M | Direct |
Footnotes
- The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 22, 2023.
- This transaction was executed in multiple trades in prices ranging from $40.815 to $41.80, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- This transaction was executed in multiple trades in prices ranging from $41.81 to $41.945, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- This transaction was executed in multiple trades in prices ranging from $42.08 to $43.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- This transaction was executed in multiple trades in prices ranging from $43.09 to $43.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- This transaction was executed in multiple trades in prices ranging from $44.10 to $44.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- This transaction was executed in multiple trades in prices ranging from $41.2651 to $42.25, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- This transaction was executed in multiple trades in prices ranging from $42.26 to $42.595, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The shares subject to the option are fully vested and exercisable.